Technical Analysis for APTO - Aptose Biosciences, Inc.

Grade Last Price % Change Price Change
F 3.76 -32.01% -1.77
APTO closed down 32.01 percent on Friday, June 11, 2021, on 11.67 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical APTO trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Volume Surge Other 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Older End-of-Day Signals for APTO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aptose Biosciences, Inc. Description

Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company's pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company's discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled Phase III clinical trial for the treatment of pancreatic cancer in combination with gemcitabine. In addition, its preclinical stage products comprise LOR-220, a novel small molecule for drug-resistant bacterial infections; and IL-17E1, an immuno-modulator for oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Drugs Immunotherapy Oncology Acute Myeloid Leukemia Targeted Therapy Pancreatic Cancer Cancer Therapies Hematologic Malignancies Bacterial Infections Small Molecule Therapies Bemcentinib Treatment Of Acute Myeloid Leukemia Phosphoinositide 3 Kinase Inhibitor Preclinical Stage Product Stage Products Drug Resistant Bacterial Infections Gemcitabine Preclinical Stage Products Pancreatic Cancers

Is APTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.3
52 Week Low 3.4
Average Volume 1,096,482
200-Day Moving Average 5.04
50-Day Moving Average 5.21
20-Day Moving Average 5.22
10-Day Moving Average 5.26
Average True Range 0.39
ADX 24.47
+DI 16.51
-DI 39.36
Chandelier Exit (Long, 3 ATRs) 4.61
Chandelier Exit (Short, 3 ATRs) 4.79
Upper Bollinger Bands 5.98
Lower Bollinger Band 4.47
Percent B (%b) -0.47
BandWidth 28.97
MACD Line -0.04
MACD Signal Line 0.06
MACD Histogram -0.0948
Fundamentals Value
Market Cap 334.12 Million
Num Shares 88.9 Million
EPS -0.59
Price-to-Earnings (P/E) Ratio -6.33
Price-to-Sales 0.00
Price-to-Book 4.32
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.66
Resistance 3 (R3) 4.72 4.47 4.51
Resistance 2 (R2) 4.47 4.24 4.44 4.46
Resistance 1 (R1) 4.12 4.10 3.99 4.06 4.41
Pivot Point 3.87 3.87 3.81 3.84 3.87
Support 1 (S1) 3.51 3.64 3.39 3.46 3.11
Support 2 (S2) 3.26 3.49 3.24 3.06
Support 3 (S3) 2.91 3.26 3.01
Support 4 (S4) 2.86